Your anger and surprise that people buy and sell biotech penny common shares makes me think this investment is not for you.
I am expecting the price to drift down more. But I believe Dr. Chan has some good news up his sleeve. He participated in the recent financing. Would he be putting up his personal money if he did not KNOW the dosing study was going well?
Good results from the dosing study, a partnership with significant upfront cash, and an out-licensing of Hemodefend or Contrastsorb would lift the price to $.75 or so. Then a RS could get the stock price and shares outstanding to a more reasonable level.
The time to buy is going to be after this stock drifts down a little more and before any of the announcements above are made.